Pharmion's Amrubicin, Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

Nov. 9, 2007 - Pharmion Corporation (Nasdaq: PHRM) today released interim findings from its Phase 2 trial of Amrubicin in second-line chemo-sensitive small cell lung cancer (SCLC). Amrubicin, the company's third-generation synthetic anthracycline, is a potent topoisomerase II inhibitor currently in development for the treatment of SCLC.... Pharmion's Press Release -